PUBLICATIONS
Selected peer-reviewed Publications
Benguigui, M., Cooper, T. J., Kalkar, P., Schif-Zuck, S., Halaban, R., Bacchiocchi, A., Kamer, I., Deo, A., Manobla, B., Menachem, R., Haj-Shomaly, J., Vorontsova, A., Raviv, Z., Buxbaum, C., Christopoulos, P., Bar, J., Lotem, M., Sznol, M., Ariel, A., Shen-Orr, S. S., … Shaked, Y. (2024). Interferon-stimulated neutrophils as a predictor of immunotherapy response. Cancer cell, 42(2), 253–265.e12. https://doi.org/10.1016/j.ccell.2023.12.005
Nassar, A. H., Kim, S. Y., Aredo, J. V., Feng, J., Shepherd, F., Xu, C., Kaldas, D., Gray, J. E., Dilling, T. J., Neal, J. W., Wakelee, H. A., Liu, Y., Lin, S. H., Abuali, T., Amini, A., Nie, Y., Patil, T., Lobachov, A., Bar, J., Fitzgerald, B., … Goldberg, S. B. (2024). Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, S1556-0864(24)00032-7. Advance online publication. https://doi.org/10.1016/j.jtho.2024.01.012
Aaron Javitt*, Merav D. Shmueli*, Matthias P Kramer, Aleksandra A. Kolodziejczyk, Ivan Cohen, Lihi Radomir, Daoud Sheban, Iris Kamer, Kevin Litchfield, Elizabeta Bab-Dinitz, Oranit Zadok, Vanessa Neins, Adi Ulman, Hila Wolf-Levy, Avital Eisenberg-Lerner, Assaf Kacen, Michal Alon, Ana Toste Rêgo, Elvira Stacher-Priehse, Michael Lindner, Ina Koch, Jair Bar, Charles Swanton, Yardena Samuels, Yishai Levin, Paula C. A. da Fonseca, Eran Elinav, Nir Friedman, Silke Meiners , Yifat Merbl. The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate anti-tumor immunity in NSCLC. Nat Cancer, 2023:4;629–647. https://doi.org/10.1038/s43018-023-00557-4. *Equal contribution.
Nicolas Girard, Jair Bar, Pilar Garrido, Marina C. Garassino, Fiona McDonal, Françoise Mornex, Andrea R. Filippi, Hans J. M. Smit, Solange Peters, John K. Field, Daniel C. Christoph, Anne Sibille, Rainer Fietkau, Vilde D. Haakensen, Christos Chouaid, Ben Markman, T. Jeroen N. Hiltermann, Alvaro Taus, William Sawyer, Allison Allen, Pratibha Chander, Muriel Licour, Benjamin Solomon, Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. Journal of Thoracic Oncology, 2023; 18(2):181-93.
Haberman Y, Kamer I, Amir A, Goldenberg S, Efroni G, Daniel-Meshulam I, Lobachov A, Daher S, Hadar R, Gantz-Sorotsky H, Urban D, Braun T, Bar J. Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefit. Sci Rep, 2023;13:2007. https://doi.org/10.1038/s41598-023-29136-4.
J. Bar, N. Peled, S. Schokrpur, M. Wolner, O. Rotem, N. Girard, F. Aboubakar Nana, S. Derijcke, W. Kian, S. Patel, H Gantz-Sorotsky, A. Zer, M. Moskovitz, G. Metro, Y. Rottenberg, A. Calles, M Hochmair, K. Cuppens, L. Decoster, M. Reck, D. Limon, E. Rodriguez, C. Astaras, A. Bettini, S. Häfliger, A. Addeo. UNcommon EGFR mutations: International Case series on efficacy of osimertinib in Real-life practice in first liNe setting (UNICORN). Journal of Thoracic Oncology, 2022 Oct 25:S1556-0864(22)01854-8
Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B. Treatment Characteristics and Real-World Progression-Free Survival in Patients with Unresectable Stage III NSCLC who Received Durvalumab After Chemoradiotherapy: Findings from the PACIFIC-R Study. Journal of Thoracic Oncology. Oct 2022; https://doi.org/10.1016/j.jtho.2022.10.003.
Akram Saad, Jeffrey Goldstein, Sarit Appel, Sameh Daher, Damien Urban, Amir Onn, Hadas Gantz-Sorotsky, Anastasiya Lobachov, Teodor Gottfried, Benjamin Spieler, Jair Bar. Chemoradiation followed by adjuvant durvalumab in stage III non–small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone. Thoracic Cancer 2022 June;13(12):1763-71. https://doi.org/10.1111/1759-7714.14452
Harel M, Lahav C, Jacob E, Dahan N, Sela I, Elon Y, Raveh Shoval S, Yahalom G, Kamer I, Zer A, Sharon O, Carbone DP, Dicker AP, Bar J, Shaked Y. Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade. J Immunother Cancer. 2022 Jun;10(6):e004582. doi: 10.1136/jitc-2022-004582. PMID: 35718373; PMCID: PMC9207924.
Cohen M, Giladi A, Oren Barboy O, Hamon P, Li B, Zada M, Gurevich-Shapiro A, Beccaria CG, David E, Maier B, Buckup M, Kamer I, Deczkowska A, LeBerichel J, Bar J, Iannacone M, Tanay A, Merad M, Amit I. The interaction of CD4 helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response. Nature Cancer, 2022: 3; 303–317.
Solomon B, Callejo A, Bar J, Berchem, Guy BL, Saintigny P, Wunder J, Raynaud J, Girard N, Lee JJ, Sulaiman R, Prouse B, Bresson C, Ventura H, Magidi S, Rubin E, Young B, Onn A, Leyland-Jones B, Schilsky R, Lazar V, Felip E, Kurzrock R. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. Cancer Med, 2022 Jul;11(14):2790-2800. doi: 10.1002/cam4.4635.
Govindan R, Lind M, Insa A, Khan SA, Uskov D, Tafreshi A, Guclu S, Bar J, Kato T, Lee KH, Nakagawa K, Hansen O, Biesma B, Kundu MG, Dunbar M, He L, Ansell P, Sehgal V, Huang X, Glasgow J, Bach BA. Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022 May;23(3):214-225. doi: 10.1016/j.cllc.2022.01.005. Epub 2022 Feb 4.
Gavert N, Zwang Y, Weiser R, Greenberg O, Halperin S, Jacobi O, Mallel G, Sandler O, Berger AJ, Stossel E, Rotin D, Grinshpun A, Kamer I, Bar J, Pines G, Saidian D, Bar I, Golan S, Rosenbaum E, Nadu A, Ben-Ami E, Weitzen R, Nechushtan H, Golan T, Brenner B, Nissan A, Margalit O, Hershkovitz D, Lahat G & Straussman R. Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer. Nat Cancer 3, 219–231 (2022). https://doi.org/10.1038/s43018-021-00325-2
Holtzman L#, Moskovitz M#, Urban D, Nechushtan H, Keren S, Reinhorn D, Wollner M, Daher S, Rottenberg Y, Rovitzky Y, Shochat T, Bar J#, Dudnik E#. dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50% #equal contribution. Clinical Lung Cancer. 2022; 23(2):122-134. https://doi.org/10.1016/j.cllc.2021.12.006
Ramalingam SS, Novello S, Guclu SZ, Bentsion D, Zvirbule Z, Szilasi M, Bernabe R, Syrigos K, Byers LA, Clingan P, Bar J, Vokes EE, Govindan R, Dunbar M, Ansell P, He L, Huang X, Sehgal V, Glasgow J, Bach BA, Mazieres J. Veliparib in combination with platinum-based chemotherapy for first-line treatment of advanced squamous cell lung cancer: A randomized, multicenter phase 3 study. Journal of Clinical Oncology. 2022;39(32):3633-3644. DOI: 10.1200/JCO.20.03318
Berger AJ, Gigi E, Kupershmidt L, Meir Z, Gavert N, Prior A, Gilad S, Harush U, Haviv I, Stemmer SM, Mardamshina M, Strauss SK, Friedlander G, Bar J, Kamer I, Reizel Y, Geiger T, Pilpel Y, Levin Y, Tanay A, Barzel B, Reuveni H, Straussman R. IRS1 phosphorylation determines a heritable probability of cancer cells to persist during EGFR inhibition therapy. Accepted to Nature Cancer, August 2021.
Cho BC, Yoh K, Perets R, Nagrial A, Spigel DR, Gutierrez M, Kim D-W, Kotasek D, Dew Rasco D, Niu J, Satouchi M, Ahn M-J, Lee DH, Maurice-Dror C, Siddiqi S, Ren Y, Altura RA, Bar J. Anti–CTLA-4 Monoclonal Antibody Quavonlimab in Combination With Pembrolizumab: Safety and Efficacy From a Phase 1 Study in Previously Treated Extensive-Stage Small Cell Lung Cancer. Lung Cancer, 159(2021); 162-170. July 2021.
Daher S, Lawrence Y, Dudnik E, Hanovich E, Urban D, Peled N, Navon R, Leibowitz-Amit R, Hammerman A, Battat E, Gottfried T, Onn A, Bar J. Nivolumab in non-small cell lung cancer: Real world long-term survival results and blood-based efficacy biomarkers. Frontiers in Oncology, July 2021. doi.org/10.3389/fonc.2021.625668
Onn A, Gottfried T, Stemmer A, Appel S, Lawrence YR Urban D, Beller T, Daher S, Bar J Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer. Cancers 2021, 13(11), 2800; https://doi.org/10.3390/cancers13112800
Johnson ML, Zvirbule Z, Laktionov K, Helland A, Cho BC, Gutierrez V, Colinet B, Lena H, Wolf M, Gottfried M, Okamoto I, van der Leest C, Rich P, Hung J-Y, Appenzeller C, Sun Z, Maag D, Luo Y, Nickner C, Vajikova A,Komarnitsky P, Bar J. Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study. Journal of Thoracic Oncology. April 03, 2021. doi.org/10.1016/j.jtho.2021.03.012
Dudnik E*, Kareff S*, Moskovitz M, Kim C, Liu SV, Lobachov A, Gottfried T, Urban D, Zer A, Rotem O, Onn A, Wollner M, Bar J. Real-world survival outcomes with immune checkpoint inhibitors in large cell neuroendocrine tumors of lung. Journal of Immunotherapy of Cancer. 2021; 9(2): e001999. doi: 10.1136/jitc-2020-001999
Dudnik E*, Moskovitz M*, Rottenberg Y, Lobachov A, Mandelboim R, Shochat T, Urban D, Wollner M, Nechushtan H, Rotem O, Zer A, Daher S, Bar J. On behalf of the Israel Lung Cancer Group. *Authors with equal contribution. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data. OncoImmunology, 2021; 10:1, DOI: 10.1080/2162402X.2020.1865653
Moser SS * Bar J*, Kan I, Ofek K, Cohen R, Khandelwal N, Shalev V, Chodick G, Siegelmann-Danieli N. Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes. Current Oncology 2021 Jan 8;28(1):317-331. doi: 10.3390/curroncol28010036. PMID: 33435584. *Equal contribution.
Kamer I, Bab-Dinitz E, Zadok O, Ofek E, Gottfried T, Daniel-Meshulam I, Hout-Siloni G, Ben Nun A, Barshack I, Onn A, Bar J. Immunotherapy response modeling by ex-vivo organ culture for lung cancer. Cancer Immunol Immunother. 70, 2223–2234 (2021). https://doi.org/10.1007/s00262-020-02828-w
Dudnik E*, Moskovitz M*, Agbarya A, Gottfried T, Shochat T, Urban D, Zer A, Rotem O, Moore A, Yust S, Peled N, Wollner M, Bar J. Alternative nivolumab duration and scheduling in advanced non-small cell lung cancer (NSCLC): a real-world evidence. International Journal of Cancer, 2020 Sept. https://doi.org/10.1002/ijc.3328.
Bar J, Perelman M, Urban D, Gottfried M, Moskovitz M, Nechushtan H, Dudnik J, Zer A, Dudnik E, Merimsky O, Onn A, Silverman B, and on behalf of the Israel Lung Cancer Group. Rising incidence of lung cancer in Arab females, Jewish females and Arab males, during 1990-2014 in Israel. Isr Med Assoc J. 2020 Dec;22(12):788-793. PMID: 33381954.
Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, Rotter-Maskowitz A, Weiser R, Mallel G, Gigi E, Meltser A, Douglas GM, Kamer I, Gopalakrishnan V, Dadosh T, Levin-Zaidman S, Avnet S, Atlan T, Cooper ZA, Arora R, Cogdill AP, Khan MAW, Ologun G, Bussi Y, Weinberger A, Lotan-Pompan M, Golani O, Perry G, Rokah M, Bahar-Shany K, Rozeman EA, Blank CU, Ronai A, Shaoul R, Amit A, Dorfman T, Kremer R, Cohen ZR, Harnof S, Siegal T, Yehuda-Shnaidman E, Gal-Yam EN, Shapira H, Baldini N, Langille MGI, Ben-Nun A, Kaufman B, Nissan A, Golan T, Dadiani M, Levanon K, Bar J, Yust-Katz S, Barshack I, Peeper DS, Raz DJ, Segal E, Wargo JA, Sandbank J, Shental N, Straussman R. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020 May 29;368(6494):973-980. doi: 10.1126/science.aay9189. PMID: 32467386.
Kamer I*, Steuerman Y*, Daniel-Meshulam I, Perry G, Izraeli S, Perelman M, Golan N, Simansky D, Barshack I, Ben-Nun A, Gottfried T, Onn A, Irit Gat-Viks#, Bar J#. Predicting brain metastasis in early stage NSCLC patients by gene expression profiling. Transl Lung Cancer Res. 2020 Jun;9(3):682-692. doi: 10.21037/tlcr-19-477. PMID: 32676330; PMCID: PMC7354143. #Equal contribution.
Bar J*, Ofek E*, Barshak I, Gotffried T, Zadok O, Kamer I, Urban D, Perelman M, Onn A. Small cell transformation as a mechanism of resistance to immunotherapy in non-small cell lung cancer. Lung Cancer, Dec 2019; 138:109–115. DOI: https://doi.org/10.1016/j.lungcan.2019.09.025.
Bar J, Markel G, Kuznetsov T, Percik R, Leibowitz-Amit R, Berger R, Golan T, Daher S, Taliansky A, Dudnik E, Shulman K, Urban D, Onn A. Acute vascular events as a possibly related adverse event of immunotherapy; a single institute retrospective study. European Journal Of Cancer. October 2019; 120: 122-131. https://doi.org/10.1016/j.ejca.2019.06.021.
*Dudnik E, *Bar J, Peled N, Bshara E, Kuznetsov T, Cohen AY, Shochat T, Nechushtan H, Onn A, Agbarya A, Moskovitz M, Keren S, Popovits-Hadar N, Urban D, Mishaeli M, Maimon Rabinovich N, Brenner R, Zer A, Rotem O, Roisman LC, Wollner M. Efficacy and safety of BRAF inhibitors (BRAFi) +/- MEK inhibitors (MEKi) in BRAF mutant (BRAFm) advanced non-small cell lung cancer (NSCLC): findings from the real-life cohort. Clinical Lung Cancer, March 2019. doi.org/10.1016/j.cllc.2019.03.007. *Equal contribution
Dudnik E, Peled N, Nechushtan H, Wollner M, Onn A, Agbarya A, Moskovitz M, Keren S, Popovits-Hadari N, Urban D, Mishaeli M, Zer A, Allen AM, Maimon Rabinovich N, Rotem O, Kuznetsov T, Shochat T, Roisman LC, Bar J, on behalf of the Israel Lung Cancer Group. BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. Journal of Thoracic Oncology, August 2018, 13(8):1128-1137
Romaniello D, Mazzeo L, Mancini M, Marrocco I, Noronha A, Kreitman M, Srivastava S, Ghosh S, Lindzen M, Salame TM, Onn A, Bar J, and Yarden Y. A Combination Of Approved Antibodies Overcomes Resistance Of Lung Cancer To Osimertinib By Blocking Bypass Pathways. Clinical Cancer Research, June 2018, DOI: 10.1158/1078-0432.CCR-18-0450
Bar J, Gorn I, Hasim MS, Baghai T, Hanson JEL, Niknejad N, Perkins TJ, Stewart DJ, Sekhon HS, Villeneuve PJ and Dimitroulakos J. Induction of Activating Transcription Factor 3 is associated with cisplatin responsiveness in NSCLC: A potential predictive biomarker of response. Neoplasia. 2016 September; 18(9): 525–535.
Bar J, Ding K, Zhao H, Han L, Laurie SA, Seymour L, Addison CL, Shepherd FA, Goss GD, Dimitroulakos J, and Bradbury PA. Angiotensin Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group study BR.24. Clin Lung Cancer. 2015 Nov;16(6):e189-201. doi: 10.1016/j.cllc.2015.05.002. Epub 2015 May 13. PubMed PMID: 26081815.
Bar J, Gorn-Hondermann I, Moretto P, Perkins TJ, Niknejad N, Stewart D, Goss G, Dimitroulakos J. Cyclin dependent kinase 6 down-regulation as a potential mechanism of acquired cisplatin resistance in non-small cell lung carcinoma. Clin Lung Cancer. 2015 Nov;16(6):e121-9. doi: 10.1016/j.cllc.2015.01.008. PubMed PMID: 25703099.
Bar J , Feniger-Barish R., Lukashchuk N, Shaham H, Moskovits N, Goldfinger N, Simansky D, Perlman M, Papa M, Yosepovich A, Rechavi G, Rotter V, Oren M, Cancer cells suppress p53 in adjacent fibroblasts. Oncogene 2009 Feb 12;28(6):933-6.